Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by LongTerm3on May 06, 2022 10:25am
165 Views
Post# 34661949

RE:Beta

RE:BetaI think the company is doing great. Even after buying back shares back they have more cash. They survived Covid, and grew the company. The financial show everything. They hired 54 people so far this year.

The stock really should of moved up more because of earnings. April was a great month to start the second quarter. The guidance s great.

The market is just weak, and people are afraid to buy. I'm okay with that, because the company is dViemed Healthcare, Inc. Fiscal Year Ends December Mar-20A Jun-20A Sep-20A Dec-20A Mar-21A Jun-21A Sep-21A Dec-21A Mar-22A Jun-22E Sep-22E Dec-22E Income Statement Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Dollars in Millions, Ex per unit measures Core Business 80.3 22.8 23.1 24.9 26.1 96.9 25.5 26.3 27.8 28.9 108.5 30.2 32.1 33.4 34.7 130.4 156.5 COVID-19 Related - 1.0 19.7 8.6 5.1 34.4 3.0 1.1 1.5 3.0 8.6 2.1 0.2 1.0 1.0 4.3 4.0 Total Revenue 80.3 23.8 42.9 33.4 31.2 131.3 28.4 27.4 29.3 32.0 117.1 32.3 32.3 34.4 35.7 134.7 160.5 Total Cost of Revenue 24.3 8.3 16.9 14.0 12.0 51.2 10.7 9.8 10.9 12.3 43.7 12.5 11.8 12.6 13.1 50.1 58.8 Gross Profit 56.0 15.6 25.9 19.5 19.2 80.1 17.7 17.6 18.4 19.7 73.4 19.7 20.5 21.8 22.6 84.6 101.7 Operating Cost and Expenses SG&A 41.4 10.6 16.4 13.6 12.3 52.8 14.5 12.9 13.3 14.2 54.9 15.8 15.5 16.5 17.2 64.9 75.9 Research And Development 0.8 0.2 0.3 0.2 0.4 1.1 0.3 0.6 0.6 0.6 2.1 0.6 0.6 0.6 0.6 2.4 2.8 Stock-based Compensation 3.9 1.2 1.2 1.2 1.3 4.9 1.3 1.2 1.3 1.3 5.2 1.3 1.4 1.5 1.5 5.7 6.6 Depreciation 0.7 0.2 0.2 0.2 0.2 0.8 0.2 0.2 0.2 0.2 0.9 0.2 0.3 0.3 0.3 1.1 1.6 Loss (gain) on Disposal of Prop & Equip 0.4 (1.2) (1.5) 0.2 0.1 (2.3) 0.1 0.1 0.1 0.1 0.4 0.2 0.2 0.2 0.6 0.8 Loss on Warrant conversion Liability / Other 0.1 - - - - (0.0) (0.0) (0.0) - (0.1) - - - - - - Other Expense - - (3.6) (0.0) (0.4) (4.0) - - - (1.5) (1.5) (0.5) - - - (0.5) - Total Operating Expenses 47.3 10.9 13.1 15.4 13.9 53.3 16.4 15.0 15.5 15.0 61.8 17.5 18.0 19.1 19.8 74.4 87.7 Operating Income (Loss) 8.7 4.6 12.9 4.0 5.3 26.8 1.3 2.7 2.9 4.7 11.6 2.2 2.5 2.7 2.9 10.3 14.0 Interest Expense / Loss on Warrant Conversion / Equity Method Investments (0.0) 0.2 0.1 0.1 0.0 0.4 (0.1) (0.1) (0.3) (0.4) (0.9) (0.3) (0.3) (0.3) (0.3) (1.0) (1.0) Net Income (Loss) Before Income Taxes 8.8 4.4 12.8 3.9 5.2 26.4 1.5 2.8 3.2 5.1 12.5 2.5 2.7 2.9 3.1 11.3 15.1 Income Taxes 0.3 0.2 (6.6) 1.1 0.2 (5.2) (0.2) 1.2 1.4 1.0 3.4 0.7 0.5 0.5 0.5 2.2 2.6 Net Income (Loss) 8.5 4.2 19.4 2.8 5.1 31.5 1.7 1.6 1.8 4.1 9.1 1.8 2.3 2.4 2.6 9.1 12.5 Net income (Loss) / share - Basic & Diluted $0.21 $0.11 $0.48 $0.07 $0.12 $0.77 $0.04 $0.04 $0.04 $0.10 $0.22 $0.04 $0.06 $0.06 $0.06 $0.22 $0.30 Adj. EPS (Excludes Tax, CARES Benefit Q2'20) $0.22 $0.11 $0.23 $0.10 $0.12 $0.55 $0.04 $0.07 $0.08 $0.09 $0.27 $0.05 $0.07 $0.07 $0.08 $0.27 $0.36 Weighted Avg. Shares Out. Basic & Diluted (M) 39.7 40.1 40.8 41.2 41.0 40.8 40.7 41.0 40.7 40.5 40.7 40.4 40.6 40.8 41.0 40.7 41.5 GAAP Net Income 8.5 4.2 19.4 2.8 5.1 31.5 1.7 1.6 1.8 4.1 9.1 1.8 2.3 2.4 2.6 9.1 12.5 Depreciation and Amortization 6.4 2.1 2.2 2.4 2.8 9.6 2.6 2.7 2.9 3.1 11.3 3.4 3.3 3.6 4.0 14.3 16.4 Interest Expense 0.3 0.2 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.3 Loss on Financial Derivative (0.4) - - - - - - Stock-based compensation 3.9 1.2 1.2 1.2 1.3 4.9 1.3 1.2 1.3 1.3 5.2 1.3 1.4 1.5 1.5 5.7 6.6 Income tax expense (recovery) 0.3 0.2 (6.6) 1.1 0.2 (5.2) (0.2) 1.2 1.4 1.0 3.4 0.7 0.5 0.5 0.5 2.2 2.6 Total Adjustments 10.5 3.6 (3.1) 4.9 4.4 9.8 3.8 5.3 5.6 5.5 20.2 5.5 5.2 5.7 6.1 22.5 25.8 Adjusted EBITDA 19.0 7.9 16.3 7.7 9.5 41.3 5.5 6.8 7.4 9.5 29.3 7.3 7.5 8.1 8.7 31.6 38.3 Growth Y/Y Revenue 24.5% 31.4% 110.8% 64.2% 45.5% 63.6% 19.4% -36.1% -12.4% 2.4% -10.8% 13.5% 17.9% 17.5% 11.8% 15.1% 19.1% Revenue - Core 24.5% 25.7% 13.9% 22.2% 21.7% 20.7% 11.8% 13.5% 11.8% 10.9% 12.0% 18.6% 22.2% 20.0% 20.0% 20.2% 20.0% Gross Profit 17.2% 19.0% 77.1% 38.5% 34.6% 43.0% 14.1% -32.0% -5.5% 2.5% -8.4% 11.3% 16.1% 18.4% 15.1% 15.3% 20.2% Adjusted EBITDA 15.1% 76.2% 295.7% 58.1% 69.8% 117.2% -30.5% -58.0% -3.9% 1.0% -29.2% 33.0% 9.3% 8.9% -9.0% 7.8% 21.4% Net Income -10.3% 116.7% 1364% -1.7% 112.4% 269.9% -60.3% -91.9% -36.2% -19.4% -71.1% 4.6% 44% 35.1% -36.5% -0.6% 37.7% Margins Gross Profit 69.8% 65.3% 60.5% 58.2% 61.5% 61.0% 62.4% 64.3% 62.8% 61.5% 62.7% 61.2% 63.3% 63.3% 63.3% 62.8% 63.4% Adjusted EBITDA 23.7% 33.1% 38.0% 23.1% 30.3% 31.5% 19.2% 25.0% 25.3% 29.9% 25.0% 22.5% 23.2% 23.5% 24.3% 23.4% 23.9% Net Income (Loss) to Common 10.6% 17.8% 45.3% 8.4% 16.3% 24.0% 5.9% 5.7% 6.1% 12.8% 7.8% 5.5% 7.0% 7.0% 7.3% 6.7% 7.8% Balance Sheet Analysis Total Cash 13.4 8.4 29.7 32.4 31.0 31.0 31.1 31.2 26.9 28.4 28.4 29.2 Total Debt (Lease) 19.5 18.7 15.5 13.2 11.1 3.5 9.6 8.6 7.6 6.5 0.7 5.9 Net Cash / Share ($0.15) ($0.26) $0.35 $0.47 $0.48 $0.67 $0.53 $0.55 $0.47 $0.54 $0.68 $0.58oing great. After next quarters numbers we should see a big move up.
<< Previous
Bullboard Posts
Next >>